Alnylam Pharmaceuticals, Inc.

Baillie Gifford is an active, team-oriented, research-based manager which is completely focused on delivering long-term returns. The firm's investment philosophy focuses on growth while their universe is global. They employ bottom-up conviction to portfolio construction. Their diversified strategies maximize investment opportunities, aiming to achieve steady returns. For equities, Baillie Gifford's analysts conduct qualitative, fundamental analysis to identify the most competitive, innovative and efficient growth companies. For multi-asset strategy, the firm invests in various asset classes such as listed equities, property, high yield credit, commodities, emerging market government bonds and insurance linked securities. For fixed-income, Baillie Gifford invests in government bonds and currencies, emerging market bonds, investment grade and high yield.

Maverick's investment process is driven by intensive, fundamental bottom-up research. They do not attempt to time the markets or focus on weightings relative to any index. Their research is augmented by a top-down view of individual industries, as well as the efforts of their quantitative research team. Maverick's investment team is organized into six industry sector teams: Consumer, Financials, Healthcare, Industrials, Media & Telecom and Technology. The industry sector teams are supported by five discipline research teams: credit, private equity, quantitative, Asia and small-cap investments.

FCM seeks to achieve superior risk-adjusted rates of return through a process of fundamental analysis that emphasizes capital preservation. The firm uses the following sources: a variety of publicly available information sources, including but not limited to financial periodicals, corporate rating services, annual reports, prospectuses and filings with the SEC and other regulators, company press releases, as well as, and to the extent applicable or appropriate, information provided by management and creditors of portfolio companies, brokers, dealers, analysts, professional asset managers, research services and hired consultants and advisers. Historically, FCM's core strategies have included merger arbitrage, credit investments, real estate investments, direct investments and long/short equity. They make investments in public and private debt and equity securities, as well as direct investments in private companies and real estate.

Investor at Alnylam Pharmaceuticals, Inc.

Cardinal Partners invests in life sciences, medical devices and healthcare information technology. The firm provides financing for early-stage companies with an investment size of $6 million to $12 million. It leads initial round of investment.

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.